Meeting
2022 ASCO Annual Meeting
A phase II study to evaluate the safety and efficacy of IMM-101 in combination with checkpoint inhibitors in patients with advanced melanoma: Final results of the IMM-101-015 trial.
Authors
Alberto Fusi
St. George's University Hospitals NHS Foundation Trust, St. George's University of London, London, United Kingdom
Alberto Fusi , Avinash Gupta , Paul Lorigan , Peter L Smith , Mike Bowles
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03711188
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9554)
DOI
10.1200/JCO.2022.40.16_suppl.9554
Abstract #
9554
Poster Bd #
147
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI).
First Author: Dirk Schadendorf
Poster
2024 ASCO Annual Meeting
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.
First Author: John Ebben
Poster
2019 Gastrointestinal Cancers Symposium
Phase II multicenter pilot study of safety, efficacy, and immune cell profiling in advanced hepatocellular carcinoma (HCC) on combination of sorafenib (SOR) plus nivolumab (NIVO).
First Author: Bridget Keenan
Poster
2018 ASCO Annual Meeting
A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma.
First Author: Adi Diab